Mobile

A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients Estudio Fase II doble ciego, aleatori...

Update Il y a 4 ans
Reference: EUCTR2008-004691-44

A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previously Chemotherapy Treated Non-Small Cell Lung Cancer Patients Estudio Fase II doble ciego, aleatorizado, de grupos paralelos, de BMS-690514 frente a erlotinib en pacientes con cáncer de pulmón no microcítico previamente tratados con quimioterapia. Revised Protocol Number 01, incorporating amendment 03 + Pharmacogenetics Blood Sample Amendment 01 (version 1.0 dated 30-Jul-08) + Protocol Amendment 02 FDG-PET Sub-Study (version 1.0 dated 19-Sep-08)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the Progression-free survival (PFS) in subjects receiving BMS-690514 relative to erlotinib.

Inclusion criteria

  • Progressive or recurrent non-small cell lung cancer (NSCLC) after treatment with one to two lines of cytotoxic chemotherapy cáncer de pulmón no microcítico progresivo o recurrente tras tratamiento con una o dos lineas de quimioterapia

Links